The study, "Medicine Use and Spending Shifts: A Review of the Use of Medicines in the U.S. in 2014," found that total dollars spent on medications in the country rose 13.1%, up from a 3.2% increase in 2013.
Drug spending in the United States last year was one for the record books. Pharmacists filled a record 4.3 billion prescriptions in 2014 that cost nearly $374 billion, according to a new report issued by the IMS Institute for Healthcare Informatics.
“The 13.1% increase in drug spending in 2014 was mainly driven by two things: the availability of new hepatitis C [HCV] treatments and very few products losing patent protection,” said Murray Aitken, IMS Health senior vice president and the executive director of the IMS Institute for Healthcare Informatics. “Sovaldi [sofosbuvir; Gilead] was the biggest drug launch in history.
“As for patent protection, the health system saves money when drugs move from branded products to generics. Typically, there has been a savings of between 15 [billion] and 30 billion a year due to patent expiries. But in 2014, that figure was only $12 billion,” he said.
Read the complete article on PainMedicineNews: http://bit.ly/1EUuScq
Dr Kathryn Lindley Explains the Importance of Cardio-Obstetrics in Fellowship Programs
December 5th 2023Kathryn Lindley, MD, FACC, Vanderbilt University Medical Center, talks about why it’s important to incorporate cardio-obstetrics training into cardiovascular disease fellowship programs.
Read More
Imetelstat Offers Benefits for Patients With MDS Who Are Red Blood Cell–Transfusion Dependent
December 5th 2023The past year has offered new hope for patients with lower-risk myelodysplastic syndromes. Besides imetelstat, which has an FDA deadline for action of June 2024, the agency approved luspatercept, which has a different mechanism of action.
Read More
Understanding the Unmet Need for Therapies to Treat Rare Bile Duct Cancer
May 24th 2022On this episode of Managed Care Cast, we bring you an excerpt of an interview with a co-chair of the 2022 Cholangiocarcinoma Foundation (CCF) annual conference, held earlier this year, about the significant unmet therapy needs facing most patients with this rare cancer.
Listen
Data From Phase 3 Trials Demonstrate Efficacy of Dupilumab for Treating COPD, Type 2 Inflammation
December 4th 2023Patients with uncontrolled chronic obstructive pulmonary disease (COPD) and type 2 inflammation had significantly better lung function at least a year into a dupilumab regimen.
Read More